TY  - CHAP
M1  - Book, Section
TI  - Rubella
A1  - Knapp, Jennifer K.
A1  - Reef, Susan E.
A2  - Boulton, Matthew L.
A2  - Wallace, Robert B.
Y1  - 2022
N1  - 
T2  - Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16e
AB  - In  1941,  an  epidemic  of  congenital  cataracts  in  Australia  was  observed  in  the  wake  of  a  large  outbreak  of  rubella.1  Until  then,  Rubella  was  considered  a  mild  and  self-limited  illness.  However,  it  assumed  new  importance  when  the  association  with  congenital  cataracts  demonstrated  its  ability  to  induce  congenital  malformations  in  infants  born  to  susceptible  women  who  acquired  rubella  during  pregnancy.  In  the  following  years,  a  broad  spectrum  of  congenital  malformations  associated  with  congenital  infection  and  Congenital  Rubella  Syndrome  (CRS)  were  described.2-4  The  subsequent  success  in  developing  and  licensing  an  effective  vaccine  to  prevent  rubella  in  1969  remains  a  major  public  health  achievement.  Until  recently,  however,  the  use  of  rubella-containing  vaccine  has  occurred  mainly  in  developed  countries.  According  to  the  World  Health  Organization  (WHO)  only  99  (51%)  countries/territories  were  using  rubella  vaccine  in  their  national  immunization  programs  in  2000,5  but  by  February  2019,  168  (87%)  countries  reported  using  rubella-containing  vaccine  in  their  national  programs.6  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/24
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1182675651
ER  -